Enzalutamide Plus ADT Boosts Survival in mHSPC

home / oncclub / enzalutamide-plus-adt-boosts-survival-in-mhspc

Andrew J. Armstrong, MD, MSc, discusses updated data from the phase 3 ARCHES trial (NCT02677896) examining enzalutamide (Xtandi) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, and the clinical implications of the research for this population.

Andrew J. Armstrong, MD, MSc

Dr. Armstrong on Updated Results of the ARCHES Trial in mHSPC

April 26th 2022

Andrew J. Armstrong, MD, MSc, discusses updated results from the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.

Andrew J. Armstrong, MD, MSc, of Duke Cancer Institute

Enzalutamide Plus ADT Demonstrates Significant Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer

April 28th 2022

Treatment with the androgen-receptor inhibitor enzalutamide plus androgen deprivation therapy led to significant survival benefits in patients with metastatic hormone-sensitive prostate cancer.

Andrew J. Armstrong, MD, MSc, of Duke Cancer Institute

Armstrong Highlights Outcomes of Final Survival Analysis of Enzalutamide Plus ADT in mHSPC

May 2nd 2022

Andrew J. Armstrong, MD, discusses the updated results and the clinical implications of the final survival analysis of the ARCHES trial, which he coauthored.